| 生物活性 |
ATI-1 is an autophagy initiation inhibitor that targets valosin-containing protein (VCP/p97), disrupting its interaction with UFL1, impairing VCP-related UFMylation homeostasis, and promoting Beclin1 polyubiquitination and degradation, thereby blocking early autophagosome formation; under nutrient deprivation, ATI-1 induces synergistic death of autophagy-dependent malignant tumor cells accompanied by decreased mitochondrial membrane potential, reduced ROS levels, and lysosomal stress, and exhibits antitumor efficacy in a pancreatic adenocarcinoma xenograft mouse model, making it applicable for research on pancreatic adenocarcinoma and lung cancer. |
体外研究 (In Vitro) |
ATI-1 (10 μM; 20 h, plus 20 μM Chloroquine (CQ) (MS-D84251) final 4 h) 可强效抑制 HeLa 细胞中自噬体的形成。 ATI-1 (5-20 μM; 24 h, plus 10 μM for 2 h under EBSS starvation) 可通过降低 Beclin1 蛋白水平并抑制自噬体形成,从而抑制 HeLa 细胞中的自噬起始;可呈剂量依赖性降低 LC3II 水平,而在饥饿条件下则会出现反常的 LC3II 积累。 ATI-1 (5-20 μM; 48 h, plus CQ co-treatment) 可通过降低 Beclin1 蛋白水平,强效抑制自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞的自噬起始;可呈剂量依赖性降低 LC3II 水平;与 CQ 联用时,还可抑制 MIA PaCa-2 细胞的自噬体形成。 ATI-1 (20 μM; 48-72 h) 可选择性抑制自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞的增殖、克隆形成能力、迁移及侵袭能力,其效力高于对自噬依赖性较弱的 HeLa 细胞的作用。 ATI-1 (30 μM; 24 h) 可破坏 VCP-UFL1 相互作用,降低 VCP 的 UFMylation 修饰,减弱 VCP-Beclin1 相互作用,并在 HeLa 细胞中选择性损伤特定 VCP 辅因子的相互作用 (VCP-ATXN3、VCP-NPLOC4)。 ATI-1 (3.13-50 μM) 以可测量的亲和力直接结合纯化的全长 VCP (Kd = 25.1 μM) 和纯化的 VCP N 端结构域 (Kd = 32.5 μM)。 ATI-1 (20 μM; 48 h) 在自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞中诱导 G1 期阻滞,但不会引发显著的细胞凋亡。 ATI-1 (5-10 μM; 2-24 h) 会加剧自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞在 EBSS 诱导的营养剥夺条件下的代谢脆弱性,进而引发非凋亡性细胞死亡、线粒体膜电位降低、ROS 水平下降以及溶酶体应激;当与饥饿处理联用时,5 μM ATI-1 可在 24 h 内使细胞活力降低约 50%-70%。
Cell Autophagy Assay
| Cell Line: |
HeLa cells |
| Concentration: |
10 μM; 20 μM CQ (final 4 h) |
| Incubation Time: |
20 h; 4 h (CQ) |
| Result: |
Markedly reduced the number of autophagosomes per cell. |
Western Blot Analysis
| Cell Line: |
HeLa cells |
| Concentration: |
10 μM (with 10 μM CQ final 2 h); 5, 10, 20 μM; 20 μM; 10 μM (EBSS starvation) |
| Incubation Time: |
24 h; 24 h; 24 h; 2 h (EBSS starvation) |
| Result: |
Prevented LC3II accumulation seen in the CQ-only group at 10 μM for 24 h with 10 μM CQ for the final 2 h. Induced a dose-dependent reduction in LC3II levels at 5, 10, 20 μM for 24 h. Reduced Beclin1 protein levels at 20 μM for 24 h. Caused a paradoxical accumulation of LC3II under EBSS starvation at 10 μM for 2 h, but autophagic flux analysis confirmed reduced LC3 puncta. |
Western Blot Analysis
| Cell Line: |
NCI-H1299 cells, MIA PaCa-2 cells |
| Concentration: |
5, 10, 20 μM (NCI-H1299); 10 μM (NCI-H1299, with 10 μM CQ final 2 h); 5, 10, 20 μM (MIA PaCa-2); 10 μM (MIA PaCa-2, with 10 μM CQ final 2 h); 10 μM (MIA PaCa-2, with 20 μM CQ final 6 h); 20 μM (NCI-H1299, MIA PaCa-2) |
| Incubation Time: |
48 h (NCI-H1299); 48 h (NCI-H1299, plus 2 h CQ); 48 h (MIA PaCa-2); 48 h (MIA PaCa-2, plus 2 h CQ); 48 h (MIA PaCa-2, plus 6 h CQ); 48 h (NCI-H1299, MIA PaCa-2) |
| Result: |
Induced a dose-dependent reduction in LC3II levels in both NCI-H1299 and MIA PaCa-2 cells over 48 h. Significantly reduced LC3II levels in MIA PaCa-2 cells at 10 μM for 48 h with 10 μM CQ for the final 2 h, with less pronounced effect in NCI-H1299 cells. Reduced yellow autophagosome/autolysosome puncta in MIA PaCa-2 cells at 10 μM for 48 h with 20 μM CQ for the final 6 h compared to CQ alone. Markedly decreased Beclin1 protein levels in both cell lines at 20 μM for 48 h. |
Cell Proliferation Assay
| Cell Line: |
NCI-H1299 cells, MIA PaCa-2 cells, HeLa cells |
| Concentration: |
20 μM |
| Incubation Time: |
72 h (CCK-8); 48 h (colony formation, wound healing, Transwell assays) |
| Result: |
Showed more pronounced growth-inhibitory effects in NCI-H1299 and MIA PaCa-2 cells than in HeLa cells, with lower IC50 values across time points. Significantly inhibited proliferation of NCI-H1299 and MIA PaCa-2 cells at 20 μM for 48 h, while HeLa cells remained relatively resistant. Markedly abrogated long-term clonogenic capacity and significantly impaired migratory and invasive potential of NCI-H1299 and MIA PaCa-2 cells. |
Cell Cycle Analysis
| Cell Line: |
NCI-H1299 cells, MIA PaCa-2 cells |
| Concentration: |
20 μM |
| Incubation Time: |
48 h |
| Result: |
Led to G1-phase arrest in both cell lines. Did not induce obvious apoptosis, with no significant increase in apoptotic populations compared to controls. |
Western Blot Analysis
| Cell Line: |
NCI-H1299 cells, MIA PaCa-2 cells |
| Concentration: |
20 μM |
| Incubation Time: |
12 h, 24 h, 48 h |
| Result: |
Did not increase γH2AX levels at any time point. Had little effect on ATXN3 abundance, unlike the canonical VCP inhibitor NMS-873 which induced robust γH2AX and reduced ATXN3 levels. |
Western Blot Analysis
| Cell Line: |
NCI-H1299 cells, MIA PaCa-2 cells |
| Concentration: |
10 μM (LC3, ROS, lysosomal, mitochondrial assays); 5 μM (cell viability, apoptosis assays) |
| Incubation Time: |
2 h (LC3, ROS, lysosomal, mitochondrial assays); 24 h (cell viability, apoptosis assays) |
| Result: |
Enhanced LC3II accumulation compared to EBSS alone when co-treated with ATI-1 and EBSS. Reduced cell viability by ~50% within 24 h at 5 μM, and up to ~70% in MIA PaCa-2 cells. No significant increase in apoptotic populations was observed. Decreased mitochondrial membrane potential, reduced ROS levels, and caused lysosomal stress with impaired membrane integrity and reduced acidic staining when combined with EBSS. |
|
体内研究 (In Vivo) |
ATI-1 (50 mg/kg;腹腔注射;每日一次;连续 14 天) 在 MIA PaCa-2 胰腺腺癌异种移植小鼠模型中展现出强效抗肿瘤功效,可显著降低肿瘤生长水平以及瘤内增殖和自噬标志物水平,且全身毒性极低。
| Animal Model: |
Nude mice |
| Dosage: |
50 mg/kg |
| Administration: |
i.p.; daily; 14 days |
| Result: |
Significantly suppressed tumor growth, resulting in reduced final tumor weights and volumes compared to controls. Markedly reduced intratumoral LC3 and Ki-67 expression. Caused no significant body weight loss or pathological abnormalities in major organs (heart, liver, spleen, lungs, kidneys). |
|